SEARCH

Entries in Apixaban (2)

Sunday
Dec092012

New Drug May Help Prevent Leg Blood Clots, Study Finds

Comstock/Jupiterimages/Thinkstock(NEW YORK) -- A new Italian study finds that the new anti-clotting drug apixaban (Eliquis) may help prevent potentially fatal blood clots in patients with deep vein thrombosis, Health Day reports.

People who suffer from venous thromboembolism are inclined to develop blood clots in their legs, which can be dangerous and even fatal if they break loose and travel to the heart, brain or lungs. Patients with DVT currently take a drug called warfarin, which is effective but carries the risk of major bleeding, sometimes fatal, Health Day says.

Nearly 2,500 patients in the study were given either 2.5 milligrams of apixaban twice daily, 5mg of apixaban twice daily or an inactive placebo. Researchers found that both doses of apixaban reduced the risk of recurrent venous thromboembolism by roughly 80 percent, compared to the placebo. And while major bleeding was similar for those taking the drug and those taking the placebo, both doses of apixaban reduced the risk of stroke, heart attack and cardiovascular-related death, according to Health Day.

The findings were published online in the New England Journal of Medicine on Dec. 8.

Copyright 2012 ABC News Radio

Thursday
Feb102011

Study: New Drug May Prevent Stroke Better Than Aspirin

Photo Courtesy - Getty Images(ONTARIO, Canada) -- Patients at risk for strokes from blood clots who take aspirin because they can't take strong blood thinning drugs like warfarin may benefit significantly from a new drug, according to a new study presented at an American Stroke Association meeting in Canada.

The study's authors compared a new blood thinning drug, apixaban, to aspirin in 5,600 patients with atrial fibrillation -- an abnormal heart beat that can increase a person’s risk of stroke from blood clots -- who could not take warfarin.  Over a period of about one year, they found that 1.6 percent of those taking apixaban suffered a stroke compared to 3.6 percent of those taking aspirin.

The findings were considered so significant that the study was stopped early.

Additionally, apixaban was just as safe as aspirin in these patients, with major bleeding events in each group being 1.4 percent and 1.2 percent for apixaban and aspirin, respectively.

Copyright 2011 ABC News Radio







ABC News Radio